Our
Research
One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable.” Our research group is reimagining druggability by using chemoproteomic approaches to tackle the undruggable proteome.
Featured Publications
Covalent degrader of the oncogenic transcription factor b-catenin
Gowans FA*, Forte N*, Hatcher J, Huang OW, Wang Y, Altamirano Poblano BE, Wertz IE, Nomura DK
JACS, 2024, 146, 16856–16865. PMID 38848252 (*co-first authorship)
Rational Chemical Design of Molecular Glue Degraders
Toriki ES*, Papatzimas JW*, Nishikawa K, Dovala D, Frank AO, Hesse MJ, Dankova D, Song J-G, Bruce-Smythe M, Struble H, Garcia FJ, Brittain SM, Kile AC, McGregor LM, McKenna JM, Tallarico JA, Schirle M, Nomura DK
ACS Central Science, 2023, 9, 915-926. (* co-first authorship)
(Novartis-Berkeley Translational Chemical Biology Institute paper)
Deubiquitinase-Targeting Chimeras for Targeted Protein Stabilization
Henning NJ*, Boike L*, Spradlin JN, Ward CC, Liu G, Zhang E, Belcher BP, Brittain SM, Hesse M, Dovala D, McGregor LM, Veldez Misiolek R, Plasschaert LW, Rowlands DJ, Wang F, Frank AO, Fuller D, Estes AR, Randal KL, Panidapu A, McKenna JM, Tallarico JA, Schirle M, Nomura DK
Deubiquitinase-targeting chimeras for targeted protein stabilization.
Nature Chemical Biology, 2022, 18, 412-421. PMID 35210618 (* co-first authorship)
(Novartis-Berkeley Center for Proteomics and Chemistry Technologies paper)
Congrats to Nafsika Forte for her paper on covalent recruitment of E2’s for targeted protein degradation
Congrats to Ethan Toriki and James Papaztimas on their discovery of rational chemical design strategies for molecular glue degraders
Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease
Novartis and UC Berkeley Extend Alliance to Tackle “Undruggable” Disease Targets and Discover New Therapeutic Modalities
